Hope S. Rugo, MD
The combination of abemaciclib (Verzenio) and pembrolizumab (Keytruda) showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer, according to early results from a pilot trial presented in a poster at the 2017 San Antonio Breast Cancer Symposium (SABCS).1
In the JPCE trial, the partial response (PR) rate at 16 weeks was 14.3% and it was 6.8% in the MONARCH-1 trial. There were no complete responses in either trial. The rate of stable disease was similar between both trials at 60.7% in JPCE and 60.6% in MONARCH-1. Fewer patients had developed progressive disease in the JPCE trial (17.9% and 25.0%). In JPCE, the disease control rate (DCR) was 75% and in MONARCH-1 it was 67.4% at the early assessment.
... to read the full story